|
 |
 |
| June 01, 2011 |
| FDA Announces New Scrutiny on Blood Clot Risk From Birth Control Pills With Drospirenone |
| Posted By DeCarli Law |
 |
Two recently-published studies on YAZ and other birth control pills containing Drospirenone have caught the attention of the U.S. Food and Drug Administration. The FDA announced yesterday that it is aware of the studies, which conclude that women using birth control pills containing
Drospirenone have a 2-to-3 times greater risk of developing blood clots compared to women using other forms of birth control.
Although the most recent studies, along with several older ones, conclude there is a significantly greater risk of blood clots from Drospirenone, a few others have found no increased risk. Prompted by the most recent studies, the FDA announced it “will look at all currently available information to fully assess the risks and benefits of drospirenone-containing birth control pills.”
Drospirenone is a type of synthetic progestin used in
YAZ and Yasmin oral contraceptives. Drospirenone is unique because it is a potassium-sparing diuretic. It’s diuretic properties mean that its use leads to less weight gain than other birth control pills. However, it also means women using it can develop abnormally high potassium levels, which itself can cause a dangerous condition called hyperkalemia.
Yasmin is also sold under the generic names Zarah,
Ocella and Zyeda. Generic forms of YAZ are Gianvi and Loryna. Both YAZ and Yasmin contain the same amount of
Drospirenone. They differ in their dosing schedule because of the amount of ethinyl estradiol (estrogen) they contain.
The FDA’s announcement states that it will continue to communicate any new safety information to the public as it becomes available. We, in turn, will pass on any further announcements from the FDA.
The complete announcement from the FDA may be found HERE.
|
|
| Continue reading "FDA Announces New Scrutiny on Blood Clot Risk From Birth Control Pills With Drospirenone" » |
|
Permalink  |
| |
| September 09, 2010 |
| Zarah, a New Generic Form of Yasmin, to Be Sold in the U.S. |
| Posted By DeCarli Law |
|
Bad news for women’s health: yet another generic form of the oral contraceptive Yasmin will be sold in the United States. Watson Pharmaceuticals, Inc. announced on Tuesday that it has received approval from the F.D.A. to sell Zarah, a generic version of
Yasmin.
Watson Pharmaceuticals obtained permission to market Zarah in the U.S. by using a procedure called an Abbreviated New Drug Application. This procedure is used to secure approval for generic drugs, and generally does not include any animal or human data to establish the drug’s safety and effectiveness.
Yasmin was previously available in generic form under the name Ocella. Yasmin, Ocella and now
Zarah contain
drospirenone and ethinyl estradiol.
Drospirenone is a synthetic progestin that acts as a potassium-sparing diuretic. This means that women using Yasmin, Ocella and
Zarah run the risk of developing abnormally high potassium levels in their bodies, which can lead to
gallbladder disease,
pulmonary embolism (PE),
deep vein thrombosis (DVT), stroke, heart attacks, and even death. Another similar birth control formulation that also comes with these risks is
YAZ, manufactured by Bayer Healthcare Pharmaceuticals.
Read HERE
to learn more about
Zarah and its risks.
Thousands of women have been injured by YAZ, Yasmin and Ocella side effects, and unfortunately, more women will now be at risk from
Zarah. If you or a loved one has suffered from any of the above side effects after using
Zarah, Yasmin, Ocella or YAZ, contact the Zarah lawyers and YAZ attorneys at DeCarli Law to learn your legal options. We provide free, no-obligation telephone consultations. You will be able to speak to an attorney, not a legal assistant or other support staff member. If we take your case, you will have no obligation to pay us fees unless we obtain a recover for you.
|
|
| Continue reading "Zarah, a New Generic Form of Yasmin, to Be Sold in the U.S." » |
|
| Permalink |
| | |
|
 |